Fig. 2From: Association of the FDA Amendment Act with trial registration, publication, and outcome reportingFDA reviewer trial interpretation and publication, along with published interpretation of the trial findings, for novel therapeutic agents in cardiovascular disease and diabetes approved by the US FDA between 2005 and 2014, pre and post the Food and Drug Administration Amendment Act (FDAAA). FDA reviewer trial interpretation as positive, equivocal, or negativeBack to article page